News & Updates

In the treatment of patients with psoriasis, the combination of adalimumab plus methotrexate is more beneficial than adalimumab alone, reducing antidrug antibody formation and inducing slightly better response, drug survival, and higher serum trough concentrations, according to a study.

Upadacitinib with topical corticosteroids shows good long-term efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD), reports a recent follow-up analysis to the AD Up study.

Psoriasis patients treated with ixekizumab show better persistence and adherence over 24 months as well as a lower risk of discontinuation than those using secukinumab, reports a recent study that used real-world data.

Ustekinumab, a human monoclonal antibody that binds to the p40 subunit of both interleukin (IL)-12 and IL-23, demonstrates effectiveness and safety in the treatment of multiethnic Asian patients with moderate to severe plaque psoriasis, according to a Singapore study.

In patients with chronic spontaneous urticaria (CSU) who remained symptomatic despite treatment, the monoclonal anti-immunoglobulin E antibody ligelizumab improved symptom control regardless of BHRA* status, as well as dermatology quality of life (QoL) regardless of angioedema status, findings from a phase IIb study have shown.

Psoriasis patients, especially those with concomitant psoriatic arthritis (PsA), suffer from worse joint pain, leading to higher analgesic use rates than the general population, a recent study has found.

Difamilast ointment is superior to vehicle and can be a safe and effective option for the treatment of atopic dermatitis, a recent study reports.